A phase III placebo-controlled comparative study of SJP-0118 in patients with bacterial conjunctivitis
Phase of Trial: Phase III
Latest Information Update: 31 Jul 2017
At a glance
- Drugs SJP 0118 (Primary)
- Indications Conjunctivitis
- Focus Therapeutic Use
- Sponsors Senju Pharmaceutical
- 28 Jul 2017 Status changed from not yet recruiting to recruiting.
- 13 May 2017 Planned initiation date changed from 28 Apr 2017 to 15 May 2017.
- 02 May 2017 New trial record